Support teaching, research, and patient care.
Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University, and a member of the National Academy of Medicine. His clinical effort is focused on patients in need of medical or surgical intervention for glaucoma and other retinal and optic nerve diseases, as well as cataract. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve, a major unmet need in glaucoma and other optic neuropathies, and his laboratory is developing novel stem cell and nanotherapeutics approaches for eye repair.Dr. Goldberg received his B.S. magna cum laude from Yale University, and his M.D. and Ph.D. from Stanford University where he made significant discoveries about the failure of optic nerve regeneration. He did his clinical training in ophthalmology and then in glaucoma at the Bascom Palmer Eye Institute, and was awarded a fellowship from the Heed Foundation. He was named the 2010 Scientist of the Year by the Hope For Vision foundation, and received the Cogan award from the Association for Research in Vision and Ophthalmology in 2012. He was elected in 2010 to the American Society of Clinical Investigation, an honorary society of physician scientists. He directs an NIH-funded research laboratory and has developed significant expertise with implementing FDA IND clinical trials for optic nerve neuroprotection and regeneration. His goal is to translate scientific discoveries to patient therapies. A partial list of clinical trials can be found on the department webpage, https://med.stanford.edu/ophthalmology/research/clinical_trials.html.
Lab research on molecular mechanisms of survival and regeneration in the visual system; retinal development and stem cell biology; nanoparticles and tissue engineering. Clinical trials in imaging, biomarker development, and neuroprotection and vision restoration in glaucoma and other neurodegenerative diseases.
Electrical Stimulation for the Treatment of Optic Neuropathies
The overall aim of this study is to see whether long-term electrical stimulation with a
home-stimulation device works well and is safe for the treatment of open-angle glaucoma.
Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than
expected regardless of your eye pressure.
View full details
Topical Insulin for Glaucoma
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile
human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic
neuropathy, and optic disc drusen).
Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell
therapy (ECT) on visual impairment related to glaucoma.
Electrical Stimulation for the Treatment of Glaucoma